drug-inhibitor combinations by using established xly determinations revealed enhanced activity when either ethambutol or cerulenin were used in combination with all antimicrobial agents for all variants except the Rg variant of strain 424, for which ethambutol was not effective. Enhanced activity with amino acid analogs was observed with the Rg colony variants of strains 373 and 424. Two potential sites for drug targeting were identified: fatty acid synthesis, for all strains assayed, and peptide biosynthesis, particularly for Rg colony variants that possess previously identified phenylalanine-containing lipopeptides as potential targets for future drug development.
Treatment of infections caused by members of the Mycobacterium avium complex is difficult because of an intrinsic resistance that these organisms have to most of the antimicrobial agents generally used to treat other mycobacterial infections (15, 22, 33) . Moreover, monotherapy of M. avium infections with clarithromycin in clinical trials is clearly associated with an increase in MICs and relapses (12) . For example, initial MICs Qf as low. as <2.0 ,ug/ml before treatment increased to .256 jig/ml at the time of relapse (18) . It is therefore apparent that better control of M. avium disease will require multiple-drug therapy with appropriate new drug combinations, particularly because the present drug regimens with commercially available drugs have not shown appreciable efficacy in eliminating infections caused by members of the M. avium complex (15, 17) .
The most likely explanation for the diverse drug susceptibility patterns of M. avium strains is the cell envelope architecture, which probably acts as an exclusion barrier for some drugs (13, 29) . Among the several components present in the M. avium cell envelope that may contribute to this drug exclusion barrier are the serovar-specific glycopeptidolipid (GPL) antigens. The GPLs are unique to the M. avium complex, and because of their noncovalent linkage in the cell envelope, they deposit themselves around the mycobacteria (4, 37) and accumulate during prolonged growth in macrophages following infection (34) . In addition, the GPLs are slowly degraded substances (21, 39) that have immunomodulatory properties (3, 9, 27) and may play a role in pathogenicity, in addition to their possible contribution to drug resistance.
In an effort to design effective drug therapy for the treatment ofM. avium, we used a combined drug-inhibitor treatment that would potentially inhibit GPL biosynthesis, thereby affecting cell envelope architecture and thus allowing more effective use of antimicrobial agents that have demonstrated efficacy in M. avium therapy. For this strategy, we used drugs that have the potential to affect GPL biosynthesis at three sites: glycosylation, peptide biosynthesis, and fatty acid biosynthesis. We have reported that this approach is capable of producing a synergistic effect when drugs which potentially inhibit GPL biosynthesis are used in combination with amikacin, sparfloxacin, and clarithromycin (5) . Those studies were an extension of an earlier report of combined treatment with m-fluoro-phenylalanine, an inhibitor GPL biosynthesis (14) , and ethambutol, an inhibitor of arabinogalactan biosynthesis (36) . That combination was effective in producing synergistic growth inhibition of M. avium (32) .
In our most recent publication regarding this combined drug-inhibitor treatment we used laboratory-maintained isolates: a smooth opaque (dome) (SmO) and a rough (Rg) variant of M. avium serovar 4 (5) . In this report we extend our observations to a clinical isolate which presented with the SmO colony morphology upon initial isolation on LowensteinJensen medium but, upon successive subculturing on 7H9 agar, segregated into distinct colony morphotypes: smooth transparent (SmT), SmO, and Rg. All three morphotypes were identified as members of the M. avium complex. We also examined the effects of combined drug-inhibitor treatment on another Rg clinical isolate to confirm the difference in susceptibility that we observed for Rg and Sm colony variants. Internal radiolabeling techniques were used to confirm the presence or absence of GPL and GPL-related components and to further confirm the presence of a unique phenylalanine-isoleucinealanine-containing lipopeptide that appears to be common to both Sm and Rg colony variants of M avium and that may also be a factor in the increased susceptibilities of Rg variants to treatment with various drug-inhibitor combinations.
MATERIALS AND METHODS Mycobacteria. The mycobacterial strains that were used in the investigation were isolated from two separate patients. Upon initial isolation at the Institut Pasteur (Paris, France), strain 373 had a characteristic Sm colony morphology on Lowenstein-Jensen medium and strain 424 had a characteristic Rg colony morphology. Both strains were identified as M avium complex by standard biochemical procedures and Genprobe analysis but were not typeable by thin-layer chromatographic (TLC) techniques (38) because they did not possess the characteristic serotype-specific GPL (C-mycoside) antigens (16) . This is not an unusual finding for Rg strains because they lack the characteristic serovar-specific GPL antigens (2, 7). However, because this finding was unusual for the Sm variant, both strains were sent to W. W. Barrow's laboratory for further examination. Subculturing of strain 424 on 7H9 agar plates (prepared by adding agar to Difco's 7H9 broth) revealed that it retained its Rg morphology. Subculturing of strain 373 on 7H9 agar resulted in three distinct colony types representing SmO, SmT, and Rg colony variants. The order of frequency was SmO > SmT > Rg. Independent examination of all four isolates by standard biochemical procedures, Genprobe and mycolic acid patterns (11) , confirmed that they were all members of the M. avium complex.
Internal radiolabeling of mycobacterial lipids. The procedure for internal radiolabeling has been published previously (21, 39) ; therefore, it will only be given here briefly. Mycobacteria were cultured in 7H9 Middlebrook broth (Difco) containing glycerol and oleic acid-albumin-dextrose. During growth,
Ile; 166 mCi/mM) (ICN Radiochemicals, Inc., Irvine, Calif.) was added at a concentration of 0.05 ,uCi/ml. In order to obtain optimum dispersal of the Rg variants, it was necessary to add glass beads (3-mm diameter) to the culture flasks (5) . Following incorporation of the radiolabel, the mycobacteria were autoclaved and harvested by centrifugation. The cells were then lyophilized and stored at -20°C until the lipids were extracted (5).
Purification of lipids. Lipids were extracted from lyophilized mycobacteria by the Folch procedure as described previously (5) . Lipids were examined by TLC by first applying 100 ,ug of lipid and then developing the plate in either chloroformmethanol-water (60:12:1) (solvent A) or chloroform-methanol (11:1) (solvent B). TLC plates were sprayed with an orcinolsulfuric acid reagent to confirm the presence or absence of GPLs (5, 8) .
HPLC procedures. Lipids were analyzed by high-performance liquid chromatography (HPLC) by using a Beckman System Gold model 126 programmable solvent delivery module controlled by System Gold chromatography software as described previously (5) . Fractions were separated on an Ultrasphere 5-,um Spherical 8.0-nm-pore-size SI analytical column (4.6 by 250 mm) attached to a guard column containing the same solid support (4.6 by 45 mm) and were detected with a 171 solid system radioisotope detector (5) . Samples were injected (400 ,ug) and were separated in a mobile phase of 100% chloroform for 10 min and then a 40-min gradient of 0 to 10% methanol in chloroform at a flow rate of 1.0 ml/min (41) . Data from DIF files were converted into graphic form by use of an Excel (Microsoft) program (10) and printed from a Macintosh PowerBook 140 as described previously (5).
Growth conditions for inhibitory studies. Growth of the mycobacteria was monitored radiometrically by means of a BACTEC 460-TB instrument (Becton Dickinson, Towson, Md.) as reported previously (35) . Growth was measured as a function of the release of 14C-labeled CO2 resulting from the metabolism of 14C-labeled palmitate in Middlebrook 7H12b broth (35) . Growth was then expressed as a numerical value, referred to as the growth index (GI), that ranges from 1 to 999 (35) .
Preparation of samples for experimental procedures was conducted as described previously (32), but is described here briefly. A vial containing 4 ml of broth (primary culture) was inoculated with 0.1 ml of mycobacterial suspension (optical density of 0.15 at 650 nm, measured with a Coleman Junior II spectrophotometer). When the primary culture had reached a GI of 500, a portion was removed and diluted 10-fold. Then, 0.1 ml of this diluted portion was injected directly into drugcontaining vials.
Interpretation of MICs was accomplished by comparing the GIs of the drug-containing vials with those of their respective controls inoculated with 100-fold fewer bacteria (1:100 control) (19) . MICs were interpreted once the GI in the control vial had reached a value of 30 or more, as described previously (19, 31) .
The x/y quotient calculation method was used to evaluate the combined drug (plus inhibitor) action (20, 32) . For this procedure, all of the drugs and inhibitors were used at sublethal concentrations. For the x/y quotient determinations, a preculture with a GI of 500 was diluted 10-fold and 0.1 ml of the suspension was injected into drug-containing vials. The combined drug-inhibitor activity was assessed by calculating x/y quotients as follows. The x value was the GI obtained with the combination of drug-inhibitor by using the BACTEC instrument, whereas the y value was the lowest GI obtained at the same time with the drug or the inhibitor used alone. For combinations, an x/y value of 1 indicated that there was no interaction between the two drugs, a quotient of <0.5 indicated enhanced drug action, whereas an xly quotient of >2 indicated the presence of antagonism between the drug and the inhibitor.
Drugs and inhibitors. The following drugs were used (concentrations are given in the appropriate tables because the MICs varied for each of the strains): amikacin, sparfloxacin, and clarithromycin. In addition, the following inhibitors were used: ethambutol, cerulenin, N-carbamyl-DL-phenylalanine, Ncarbamyl-L-isoleucine, trans-cinnamic acid, m-fluoro-phenylalanine, and 1-fluoro-l-deoxy-P-D-glucose (Sigma Chemical Co., St. Louis, Mo.). Sparfloxacin (Rhone D.P.C. Europe, Antony, France), amikacin (Bristol, Paris, France), and clarithromycin (Abbott Laboratories, North Chicago, Ill.) were kindly provided by their manufacturers. For stock solutions of clarithromycin, N-carbamyl-L-isoleucine, and m-fluoro-phenylalanine, methanol was used to dissolve the drugs, and in the case of cerulenin, absolute ethanol was used (5) . All other inhibitors and drugs were dissolved in distilled water and the stock solution was sterilized by filtration through a 0.22-,um-poresize filter before addition to test vials (5) . Appropriate controls were included to ensure that the inhibitory effects of the drugs were not due to the addition of solvent. Fig. 2A) and strain 373 (Fig. 2D ) revealed a complete absence of GPL antigens and apolar GPL. Only one major peak was observed; that peak had a retention time identical to that of a Phe-Ile-Ala-containing lipopeptide that we described previously in both Sm and Rg variants of M. avium (5) . This peak was also observed in lipid extracted from the SmO, SmT, and Rg variants of strain 373 (Fig. 2B to D,  respectively) . Although the relative height for peak I, in the case of the SmO variant, appears to be small in comparison with those for the SmT and Rg variants of the same strain, it should be noted that the peak areas were very similar for all three variants. The areas for peak I for SmO, SmT, and Rg variants was 3,165, 3,176, and 3,417 cpm, respectively. One of the reasons for this difference in [14C]Phe incorporation into peak I was the presence of other phenylalanine-containing lipopeptides (retention time, 25 to 27 min) that had incorporated most of the radiolabel (Fig. 2B) . Because of this, the amount of peak I appeared to be reduced in the case of the SmO variant. Although not further characterized, these phenylalanine-containing lipopeptides have retention times similar to those of phenylalanine-containing lipopeptides reported previously in M. avium serovar 4 (5, 40) and serovars 8 and 20 (40) and may play a role in GPL biosynthesis (5). The area for peak I of the Rg strain 424 was 47,828 cpm; however, that strain grew faster and produced a better cell yield than did the three variants of strain 373.
Peaks corresponding to GPL were observed in lipid from SmT (Fig. 2C) . The locations of GPLs in HPLC fractions were confirmed by analysis on TLC plates by using the orcinolsulfuric reagent (23) . Confirmation of radiolabel incorporation was accomplished as described previously by hydrolysis of appropriate HPLC fractions in HCl and analysis by means of cellulose TLC by using authentic amino acid standards and scintillation counting of the corresponding sections on cellulose TLC plates (21, 41 bial agents varied, with the SmT and Rg variants of strain 373 being more resistant to sparfloxacin ( Table 1 ). The one exception was with ethambutol, whose MIC was the same for all three variants (Table 1) .
Radiometric determinations for combined drug treatment.
By using the xly quotient calculations established previously (32) , the results obtained from combined drug-inhibitor action for all of the variants of M. avium were assessed and are given in Tables 2 through 5 . In addition, representative radiometric data for some of the combinations and parallel controls are given in Fig. 4A through C. For all three colony types of strain 373, an enhanced drug-inhibitor activity was observed for combinations that included ethambutol or cerulenin (Tables 2  through 4 and Fig. 4A and B is given for the enhanced activity of ethambutol or cerulenin plus an antimicrobial agent (i.e., amikacin, sparfloxacin, and clarithromycin) in the case of strain 373 SmO and SmT (Fig.  4A) because the results were very similar. Graphic results for the other drug-inhibitor combinations are not given because there was no enhanced activity for the SmO or SmT variants of strain 373. No enhanced activity was observed for combinations with ethambutol in the case of the Rg variant of strain 424, even though the ethambutol MIC for that strain was equivalent to those for the variants of strain 373 (Tables 1 and  5 ). For the Rg colony variant of strain 373 (Tables 2 through 4 and Fig. 4B ) and the Rg variant of strain 424 (Table 5 and Fig.   4C ), an enhanced drug-inhibitor activity was additionally observed for antimicrobial combinations that included either N-carbamyl-phenylalanine, N-carbamyl-isoleucine, trans-cinnamic acid, or m-fluoro-phenylalanine. No enhanced activity was observed for any of the strains when antimicrobial combinations included 2-deoxy-D-glucose (data not shown), and (Table 4) .
DISCUSSION
Because of its diversified drug resistance patterns to most antimycobacterial agents, the M. avium complex presents a major problem in the clinical management of human immunodeficiency virus-infected patients. It is apparent that to achieve successful treatment of M. avium infections it will be necessary to use appropriate drug combinations. Although antimicrobial combinations have been used with some success, there remains a need for improved drug therapy for these drug-resistant opportunistic pathogens. Newer types of treatment should be examined to accomplish the necessary improvement in therapy that is required, particularly in the case potential inhibitors of GPL biosynthesis were used in combination with amikacin, sparfloxacin, and clarithromycin (5) . As a continuation of those studies, we report here on the increased activities of those same antimicrobial agents with additional potential inhibitors of GPL biosynthesis by using clinical isolates that represent the three major colony variants isolated from patients: SmO, SmT, and Rg.
Using a strategy similar to that reported previously (5), we chose drugs that had the potential to inhibit GPL biosynthesis at three sites: glycosylation, peptide biosynthesis, and fatty acid biosynthesis. The two drugs used to inhibit glycosylation were 2-deoxy-D-glucose and 1-fluoro-1-deoxy-D-glucose. These two drugs did not demonstrate low MICs and, with one exception, did not produce increased levels of activity when used in combination with any of the antimicrobial agents. This was not unexpected with the Rg variants, because they lack the ability to synthesize the GPL and would thus not be expected to respond (5) . We were surprised to see a lack of activity in the case of the SmT because it appears that that variant does synthesize GPL. Because of our previous findings with 2-deoxy-D-glucose (5), we expected some increased activity. However, the lack of activity with regard to the SmO variant was probably due to the apparent lack of GPL, as evidenced by TLC and HPLC examination.
N-Carbamyl-DL-phenylalanine, N-carbamyl-L-isoleucine, transcinnamic acid, and m-fluoro-phenylalanine were used to inhibit peptide synthesis. These drugs did show increased levels of activity, but only in the case of the Rg variants. This was expected because similar drugs produced that same effect with a Rg variant of M avium serovar 4 (5) . It has been demonstrated that N-carbamyl-DL-phenylalanine (14) and m-fluorophenylalanine (14, 30, 32) inhibit GPL biosynthesis, which probably weakens the cell envelope (30) and allows access of the antimicrobial agents into the cell.
To inhibit fatty acid biosynthesis we again chose cerulenin. Cerulenin has low MICs and, in all cases that we have examined, results in increased drug-inhibitor activities for all three colony variants. Cerulenin has previously been shown to have low MICs for M. avium (26) , but to our knowledge our studies are the only ones that demonstrate its effectiveness in drug-inhibitor combinations. Because the mycobacterial cell ,ug/ml) (A), N-carbamyl-DL-phenylalanine (50 jig/ml) (0), N-carbamyl-L-isoleucine (100 jig/ml) (A), trans-cinnamic acid (100 jig/ml) (0), or m-fluoro-phenylalanine (50 jig/ml) (E) on M. (1, 5, 40, 41) . This component is a nonglycosylated lipopeptide that contains phenylalanine, alanine, and isoleucine (5) and may play a role in GPL biosynthesis (40, 41) . Also observed in the SmO variant of strain 373 was a cluster of phenylalanine-containing peaks with HPLC retention times a few minutes later than peak I. These apparently represent a major pool of components because of the amount of radiolabeled phenylalanine that was incorporated. Although not investigated in detail in the present study, it is very likely that at least one of these is similar to a glycosylated lipopeptide that we identified previously (1, 5, 40, 41) . Because of the presence of phenylalanine, threonine, alanine, and alaninol, it most likely represents a precursor in GPL biosynthesis (5) . Similar lipopeptides have been identified in M. avium, and they have been suggested to play a role in GPL biosynthesis (7).
Thus, as proposed previously (14) , it appears that GPL biosynthesis proceeds by way of an initial fatty acyl-peptide core. It is likely that by inhibiting the biosynthesis of the lipopeptide cores it would be possible to inhibit initial events in GPL biosynthesis. Rg isoleucine:alanine was reported to be 2:2:1 (24), which is slightly different from that of peak I, which is 2:1:2, respectively (5). Peak I represents a major lipopeptide in Rg strains lacking serovar-specific GPL. This may be a partial explanation for their increased susceptibilities to inhibitory drugs with structural similarity to phenylalanine and isoleucine (5; this paper). Complete structural analysis of this lipopeptide is being conducted.
With regard to the three colony variants of strain 373, it appears that only the SmT variant contains serovar-specific GPL; this is usual. However, the fact that the SmO variant does not contain TLC-detectable serovar-specific GPL is surprising.
To our knowledge, this has not been reported previously. The SmO variant of strain 373 does contain the serovar-nonspecific apolar GPL, as evidenced by HPLC and TLC, and may be a mutant which can be used in discerning the GPL biosynthetic pathway. Further studies are necessary to confirm that assumption. The absence of serovar-specific GPL in the Rg variant was expected because of previous studies (2, 6); however, Rg variants can still synthesize the lipopeptide core portion of the GPL (5, 7, 40) .
It is interesting that of the three variants of strain 373, the From the results of the studies discussed here we can suggest two potential sites to which inhibitory drugs useful in the treatment of M. avium should be directed in the future. For all strains that we have examined (5; this paper), cerulenin has consistently shown low MICs and increased levels of activity when used in combination with antimicrobial agents at sublethal concentrations. Cerulenin is an inhibitor of fatty acid synthesis but is not useful as an antimicrobial agent because it is metabolized rapidly in the host (25, 26) . Even so, the data in this paper suggest that the fatty acid synthetase system would be a plausible biosynthetic target for drugs developed in the future.
With regard to M. avium Rg variants, a potential target for drugs developed in the future appears to be peptide biosynthesis. In all the Rg strains that we tested (5; this paper), combined antimicrobial treatment with inhibitory drugs structurally analogous to phenylalanine has shown increased levels of activity, even sometimes when MICs are high (this paper). Although increased levels of activity with phenylalanine analogs have been demonstrated in the case of some Sm strains (5, 30, 32) , the effects are not as dramatic as they are with Rg variants (5; this paper). Indeed, analogs of phenylalanine have been reported to inhibit GPL biosynthesis without inhibiting the growth of the organism (14) . If the assumption that M. avium drug resistance is largely due to cell envelope impermeability is correct (13, 29) , then these results suggest that the integrity of the cell envelope in the case of Rg variants depends more on components susceptible to phenylalanine-analogous drugs. The potential for lipopeptide biosynthesis being a good drug target is further supported by the results with drugs structurally analogous to isoleucine. Although the specific site for the action of these drugs is not yet known, it is plausible to suggest that the phenylalanine-isoleucine-containing lipopeptide may offer a reasonable explanation for that activity. All of these studies will have to be confirmed in a cell-free system (28) and are in progress.
